Replies to post #292588 on Anavex Life Sciences Corp (AVXL)

[Simonizer]

The was three 2-73 questions in a row. Did I hear her say I’ll have to call over to the company to see if they have been approved for Rett’s yet?

[polarbear77]

Steadyt I didn’t get to listen to the presentation however, there are 2 other rare disorders that were referenced in the recently issued new patent 11/30/2020: Williams Syndrome and Smith-Magenis Syndrome. See examples 6 & 7. One of these could be the yet-to-be-announced indication for another new trial in 2021:







“Example 6

Williams Syndrome--Weight Gain

[0062] A 2 year-old male presents with Williams syndrome. He exhibits a failure to thrive with low weight gain. He begins treatment with i.v. doses of A2-73 at 5 mg every other day. After 60 days of treatment, he exhibits a 10% weight gain.







Example 7

Smith-Magenis Syndrome--Sleep

[0063] A 5 year-old male presents with Smith-Magenis syndrome. He experiences disturbed sleep. He begins treatment with oral doses of A2-73 at 10 mg/day. After 15 days of treatment, his sleep is markedly less disturbed.”






https://www.anavex.com/anavex-life-sciences-announces-notice-of-allowance-for-u-s-patent-application-with-expanding-claims-covering-anavex2-73-blarcamesine-for-the-treatment-of-rett-syndrome-and-other-neurodevelopm/







https://uspto.report/patent/app/20200246303